Vibrant Therapeutics Raises $61m to Advance VIB305 and Intelligent Pipeline

Biotech Funding & Regulatory News

Vibrant Therapeutics Raises $61m in Funding to Advance Intelligent Therapeutics Pipeline

Vibrant Therapeutics, a clinical-stage biotechnology company specialising in intelligent therapeutics, has announced the successful closing of $61 million in new financing. This capital injection accelerates the development of its proprietary platform and lead candidate, VIB305.

New Financing

$61 Million

+ New Investors

Total Capital Raised

$100 Million

To date

Key Investors

• Pfizer Ventures
• Apricot Capital

The financing round included participation from new high-profile investors Pfizer Ventures and Apricot Capital. The funds will be utilized to advance Vibrant's pipeline of intelligently designed therapeutics and further develop its proprietary platform for drug design.

"Vibrant’s intelligently designed logic-gated approach to developing next-generation therapeutics represents a compelling opportunity, potentially in multiple therapeutic areas."

Michael Diem

Senior Managing Partner & VP, Worldwide Business Development at Pfizer Ventures

FDA IND Acceptance for VIB305

Alongside the funding news, Vibrant announced a significant regulatory milestone: the US Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for the company's lead programme, VIB305.

About VIB305 Phase 1 (AUS/CN) IND Accepted (USA)

VIB305 is a masked T-cell engager (TCE) prodrug designed with precision in mind. Its mechanism of action involves:

• Selective Activation: Activates specifically within the microenvironment of a tumour.
• Tissue Sparing: Designed to spare healthy tissues surrounding the tumour.
• Target Indication: Epidermal growth factor receptor (EGFR)-expressing solid tumours.

Current Status: VIB305 is already being studied in Phase 1 clinical trials in Australia and China. The FDA acceptance now clears the path for US clinical trials.

"Vibrant represents the type of platform-driven company we seek to support – one that pairs innovative science with a clear path to global development. The company’s logic-gated approach and rapid progress with VIB305 underscore its potential to meaningfully expand the therapeutic window in solid tumours."

Arthur Qiang

Managing Partner at Apricot Capital